Abstract. The proliferation and migration of vascular smooth muscle cells are significant in the development and progression of atherosclerosis and plaque rupture. Metformin is a widely used antidiabetic drug, which has been reported to inhibit cell growth and migration. The antiproliferative and antimigratory effects of metformin have been attributed to 5' adenosine monophosphate-activated protein kinase (AMPK) activation. The purpose of the present study was to investigate the effects of metformin on primary human aortic muscle cells (HASMCs) in vitro and to clarify the underlying mechanism. We investigated the effectiveness of metformin in inhibiting the proliferation and migration of HASMCs in vitro using RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR), cell number counting, cell viability assay, cell cycle assay and cell migration assay. Through transfection with small interfering (si)RNA targeting p53 and interferon-inducible protein 16 (IFI16), the roles of p53 and IFI16 in these processes were evaluated. The present study demonstrated that p53, IFI16 and AMPK were upregulated in senescent primary HASMCs, which exhibited a decrease in proliferation and migration. In addition, metformin was able to activate p53, IFI16 and AMPK, in order to inhibit proliferation and migration of HASMCs. Furthermore, siRNA-mediated knockdown of p53 and IFI16 attenuated AMPK activation and reversed the suppressive effects of metformin. Notably, in response to metformin, the activation of AMPK was not observed in p53-and IFI16-silenced HASMCs. These results indicated that metformin-induced activation of AMPK suppresses the proliferation and migration of HASMCs by upregulating p53 and IFI16. These findings suggested that metformin may have potential use in the treatment of atherosclerosis.
Introduction
Atherosclerosis is a complex, chronic progressive disease, and a major cause of mortality worldwide (1, 2) . The atherosclerotic process comprises three steps: Fatty streak formation, atheroma formation and atherosclerotic plaque formation (3) . Serious clinical consequences of atherosclerosis, including myocardial infarction and stroke, are caused by acute rupture of unstable plaques (4) . The proliferation and migration of vascular smooth muscle cells are important in the pathogenesis of atherosclerosis and in the rupture of unstable plaques (5) (6) (7) .
Metformin is a biguanide class drug, which is widely used for the clinical treatment of type 2 diabetes mellitus (8) ; its fundamental use is to suppress gluconeogenesis and promote glucose metabolism (9) . Previous studies have reported that metformin exerts vascular protective effects beyond its role in treating diabetes (10, 11) . A recent study indicated that metformin is associated with the suppression of diabetes-accelerated atherosclerosis (12) . In addition, it has been suggested that metformin may have a role in preventing and treating atheroma, and protecting against plaque rupture (13) . Furthermore, metformin may inhibit smooth muscle cell proliferation and migration (14, 15) .
I n response to metfor m i n, at a x ia tela ngiectasia-mutated (ATM) protein is phosphorylated at Ser-1981 (16) . It has been reported that ATM activates p53 via phosphorylation of Ser-15, in response to DNA damage (17) . p53 is regarded as a powerful suppressive factor that is capable of halting cell proliferation and inhibiting migration (18, 19) . Previous studies have indicated that p53 serves a key role in metformin-mediated growth inhibition in numerous types of tumor cell (20) (21) (22) . In addition, activated p53 can activate 5' adenosine monophosphate-activated protein kinase (AMPK) (17) . The suppressive effects of metformin are closely associated with AMPK activation (14, 23) , which can induce cell cycle arrest (23, 24) . However, the signaling pathways and downstream effectors underlying the effects of metformin remain to be elucidated. As a member of the p200 protein family, interferon-inducible protein 16 (IFI16), has been reported to have a central role in regulating cell proliferation by interacting with various cellular modulators (25) . p53 can upregulate IFI16 in human diploid fibroblasts (HDFs) (26) , whereas knockdown of IFI16 results in a reduction of AMPK in HDFs (27) . However, the molecular mechanism by which IFI16 upregulation is induced by metformin remains to be fully elucidated.
Metformin-induced activation of AMPK inhibits the proliferation and migration of human aortic smooth muscle cells through upregulation of p53 and IFI16
Based on these previous findings, the present study demonstrated that metformin inhibits the proliferation and migration of human aortic smooth muscle cells (HASMCs) via AMPK activation. In addition, the roles of p53 and IFI16 in metformin-mediated suppressive effects on HASMCs were identified. Notably, the present study provided a novel insight into the mechanisms underlying metformin-mediated HASMC proliferation arrest and migratory inhibition in atherosclerosis development and progression.
Materials and methods
Cell culture. Primary HASMCs were obtained from ScienCell Research Laboratories, Inc. (San Diego, CA, USA). According to the manufacturer's records, HASMCs were obtained from a donor, the details of which are as follows: Age, 20 weeks; sex, female; race, unknown. HASMCs were cultured in smooth muscle cell medium (SMCM; ScienCell Research Laboratories, Inc.) supplemented with 5% fetal bovine serum (ScienCell Research Laboratories, Inc.), 1% smooth muscle cell growth supplement (ScienCell Research Laboratories, Inc.), 100 U/ml penicillin and 100 U/ml streptomycin. Cells were incubated at 37˚C in a humidified atmosphere containing 5% CO 2 .
RNA interference. p53 small interfering (si)RNA (sense, 5'-gCAUgAACCggAggCCCAU-3' and antisense, 5'-AUg ggCCUCCggUUCAUgC-3'), IFI16 siRNA (a pool of 3 different siRNA duplexes: sc-35633A sense, 5'-CCACAAU CUACgAAAUUCA-3' and antisense, 5'-UgAAUUUC gUAgAUUgUgg-3'; sc-35633B sense, 5'-CCAUCCAgC AgUUUCUUCA-3' and antisense, 5'-UgAAgAAACUg CUggAUgg-3'; sc-35633C sense, 5'-ggAAggAgAUA AACUgAAA-3' and antisense, 5'-UUUCAgUUUAUC UCCUUCC-3'), control siRNA, control siRNA (fluorescein-conjugated), siRNA transfection reagent and siRNA transfection medium were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Briefly, HASMCs (1x10 5 cells/ml) were transiently transfected with siRNA (concentration, 0.06 mmol/l) according to the manufacturer's protocol. After adding the siRNA, the cells were incubated for 5-7 h at 37˚C in a CO 2 incubator. A total of 48 h post-transfection, cells were processed for immunoblotting, cell cycle analysis and immunofluorescence, or were treated with various concentrations of metformin (Sigma-Aldrich; Merck KgaA, Darmstadt, germany; dissolved in 1X PBS) and incubated for an additional 24 h at 37˚C. RNA-silenced HASMCs were treated with various concentrations of metformin (0, 10 mM) at 37˚C for 24 h (RNA-silenced group; RNA-silenced + metformin group).
Senescence-associated β-galactosidase staining (SA-β-gal).
The SA-β-gal activities of young (passage number 3) and old (passage number 7) HASMCs were detected using a SA-β-gal staining kit (Beyotime Institute of Biotechnology, Shanghai, China) according to the manufacturer's protocol. The number of blue cells (SA-β-gal-positive cells) and the total number of cells in six randomly chosen fields were counted to calculate the percentage of senescent cells using an ordinary optics microscope (Olympus Corporation, Tokyo, Japan). Percentage of senescent cells = (number of SA-β-gal positive cells/number of total cells) x 100%.
Cell cycle analysis. Cells from each group (1x10 6 cells) were washed with PBS, trypsinized, centrifuged at 167.7 x g at 4˚C for 5 min, resuspended in 3 ml 75% ethanol and stored at 4˚C overnight. The cells were then centrifuged, resuspended in 200 µl PBS supplemented with 10 µg/ml RNase A and were incubated at 37˚C for 30 min. Subsequently, the cells were stained with propidium iodide (PI) solution (0.1% sodium citrate, 0.1% Triton X-100, and 50 µg/ml PI; BestBio, Shanghai, China) at 4˚C for 30 min. Cell cycle progression was analyzed using a BD FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA), and data analysis was conducted using FlowJo 7.6 software (FlowJo, LLC, Ashland, OR, USA).
Cell viability assay. Cells were seeded at a density of 8,000 cells/well in 96-well plates containing 0.1 ml complete medium in triplicate. On the following day, cells were exposed to various concentrations of metformin and were cultured for 24 h. Cell viability was determined using a Cell Counting kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Shanghai, China) assay. After incubation with CCK-8 solution for 2 h at 37˚C, absorbance was determined at a wavelength of 450 nm using a SpectraMax 190 Microplate Reader (Molecular Devices, LLC, Sunnyvale, CA, USA).
Cell counting. Cell proliferation was evaluated by cell counting after cells seeded into 6-well culture plates (1x10 5 cells/well) had been incubated at 37˚C with different treatments. The total cell number was then counted in 4 fields using a hemocytometer and the mean values were calculated from 3 replicates. The cells were counted using a phase contrast microscope (Olympus Corporation).
Transwell assay. HASMCs (0.5x10 5 cells) were resuspended in 0.1 ml serum-free SMCM and were seeded into the upper Transwell chamber (8 µm pore size, 24-well; Corning Life Sciences, Tewksbury, MA, USA), whereas 0.8 ml complete SMCM was used as a chemoattractant, which was added into the lower chamber. After 24 h at 37˚C, the cells that migrated through the membrane to the lower surface were fixed with methanol for 20 min and were then stained with 0.1% crystal violet solution for 20 min. Finally, the stained cells were counted under an inverted microscope. Six random fields were chosen for analysis of cell motility.
RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total cellular RNA was extracted from the untreated controls, metformin-treated, control siRNA-transfected, p53 siRNA-transfected and IFI16 siRNA-transfected HASMCs using Total RNA fast extraction kit (Fastagen, Shanghai, China) according to the manufacturer's protocol. Total RNA (1 µg) underwent cDNA synthesis using Takara PrimeScript™ RT reagent kit (Takara Bio, Inc., Otsu, Japan) according to the manufacturer's protocol. RT-qPCR was performed in a 10 µl volume, using SYBR-green PCR Master mix (Takara Bio, Inc.) on a Roche LightCycler ® 480 system (Roche Diagnostics gmbH, Mannheim, germany) according to the manufacturers' protocols. Thermal cycling conditions were as follows: One cycle at 95˚C for 10 min, followed by 45 cycles at 95˚C for 10 sec and 60˚C for 30 sec. A PCR reaction mixture was prepared. The reaction then started (stage 1, 1 cycle at 95˚C for 10 min; stage 2, 45 cycles at 95˚C for 10 sec, 60˚C for 30 sec). PCR amplification was conducted using the following primer sequences: p53 (239 bp), forward 5'-CTCCTCAgCATCTTATCCgAg-3', reverse 5'-gCT gTTCCgTCCCAgTAgATTA-3'; IFI16 (80 bp), forward 5'-gAAgTgCCAgCgTAACTCCTA-3', reverse 5'-TACC TCAAACACCCCATTCAC-3'; AMPK (132 bp), forward 5'-TgTgACAAgTACATACTCCAA-3', reverse 5'-gATC TCTgTggAgTAgCAg-3'; and gAPDH (697 bp), forward 5'-TCACCATCTTCCCAggAgCgAg-3' and reverse 5'-TgTC GCTGTTGAAGTCAGAG-3'. Relative quantification values were calculated using the 2 -ΔΔCq method (28) .
Western blot analysis. Whole-cell extracts were homogenized in extraction buffer (Beyotime Institure of Biotechnology). Equal amounts of lysate were separated by 8-12% SDS-PAgE and were transferred onto polyvinylidene fluoride membranes (Beyotime Institute of Biotechnology). The protein was quantified using BCA Protein Assay kit (Beyotime Institure of Biotechnology). A total of 40 µg (4 µg/µl x10 µl) protein was loaded onto the gels. The membranes were blocked with 5% nonfat dry milk and were then incubated with the recommended concentration of primary antibody overnight at 4˚C. The mem branes (needless primary antibodies) were washed three times (15 min/wash) and were then incubated with a 1:5,000-1:10,000 dilution of peroxidase-conjugated goat anti-rabbit (1:10,000; cat. no. 9101) and goat anti-mouse (1:10,000; cat. no. 9100) secondary antibodies (Origene Technologies, Inc., Beijing, China) for 1 h at room temperature. Finally, the membranes (needless secondary antibodies) were washed three times (15 min/wash). Blots were visualized using an enhanced chemilumines cence buffer and an Amersham Imager 600 (gE Healthcare, Chicago, IL, USA). The data were analyzed with ImageJ software v2. 
Results

Senescent primary HASMCs exhibit a decrease in proliferation and migration.
To determine the proliferative and migratory capabilities of HASMCs, HASMCs were investigated at different passage numbers. Pre-senescent HASMCs (passage number 3; young) exhibited a small and spindle-like morphology, whereas post-senescent HASMCs (passage number 7; old) appeared morphologically flattened with enlarged shapes; these cells were more positive for the recognized biomarker of senescence (SA-β-gal) ( Fig. 1A and B) . After cell counting, the present study indicated that the number of old cells was significantly lower compared with the number of young cells after the first 24-h culture (Fig. 1C) . In addition, the viability of senescent HASMCs was markedly decreased after a 24-h culture, according to the results of the CCK-8 assay (Fig. 1D ). As shown in Fig. 1E and F, the proportion of cells arrested at g 1 phase of the cell cycle was evidently increased, and the percentage of cells at S phase was markedly decreased among the old cells compared with the young cells. The results of a cell migration assay indicated that the migratory capabilities of the old cells were markedly reduced compared with the young cells ( Fig. 1g and H) .
Protein expression levels of p53, IFI16, AMPK and p-AMPK are increased in old
HASMCs. The present study aimed to detect the relative expression levels of proteins associated with growth arrest and migratory inhibition in senescent HASMCs. As shown in Fig. 2A and B, the basal levels of p53, IFI16, AMPK and p-AMPK were higher in the protein extracts derived from old HASMCs compared with in those derived from young HASMCs. Immunofluorescence analysis indicated that endogenous p53 expression (green) was increased in the old cells compared with in the young cells ( Fig. 2C and D) . In addition, the expression levels of endogenous IFI16 (red) were increased in old HASMCs (Fig. 2E and F) .
Metformin upregulates p53, IFI16 and p-AMPK expression, and inhibits proliferation and migration of HASMCs.
To explore whether the suppressive effects of metformin were associated with the extent of relative protein activation in HASMCs, a dose-dependent immunoblot analysis was conducted. HASMCs (passage 3) were treated with various concentrations of metformin (0-10 mmol/l) for 24 h. As shown in Fig. 3A , the mRNA expression levels of p53 and IFI16 were increased in a dose-dependent manner following treatment with metformin. The protein expression levels of p53, p-p53 (Ser-15), IFI16 and p-AMPK (Thr-172) were also steadily increased in response to increasing metformin concentrations ( Fig. 3B and C) .
As shown in Fig. 4A and B, incubation of the cells with increasing metformin concentrations resulted in an inhibition in cell growth and reduced cell viability. Similar to the effects of senescence on cell cycle progression, metformin was able to arrest HASMCs in g 1 phase and decreased the percentage of cells in S phase of the cell cycle in a dose-dependent manner ( Fig. 4C and E) . Furthermore, increasing metformin concentrations resulted in a gradual, significant reduction in the migration of HASMCs (Fig. 4D and F) .
p53-knockdown significantly suppresses metformin-mediated growth arrest and migratory inhibition in HASMCs.
To explore the role of p53 in metformin-mediated growth arrest and migratory inhibition, p53 was knocked down using p53 siRNA, and the effects of metformin on p53-silenced HASMCs were reassessed. The present study initially confirmed that p53 was knocked down in p53 siRNA-transfected HASMCs. Cell immunofluorescence analysis indicated that endogenous p53 expression was evidently attenuated in cells transfected with p53 siRNA (Fig. 5A and B) . Furthermore, p53-knockdown resulted in a significant reduction in the expression levels of IFI16, AMPK and p-AMPK (Fig. 5C and D) . With regards to mRNA expression, p53, IFI16 and AMPK expression was significantly reduced in p53 siRNA-transfected cells (Fig. 5E) .
A total of 24 hours after culture, the results indicated that p53-silenced cells exhibited increased proliferation, which was resistant to metformin-induced growth arrest (Fig. 6A) . Analysis of cell cycle progression indicated that the percentage of g 1 phase cells was significantly decreased and the percentage of S phase cells was increased in p53-silenced HASMCs. Notably, p53-knockdown evidently suppressed the metformin-mediated increase in the accumulation of HASMCs in g 1 phase of the cell cycle ( Fig. 6B and C) . Furthermore, cell viability was markedly increased in the p53-silenced cells, whereas the metformin-mediated decrease in cell viability was suppressed by knockdown of p53 (Fig. 6D) . Cell migration analysis indicated that knockdown of p53 promoted an increase in mobility. As expected, metformin-induced migratory inhibition was markedly suppressed in HASMCs when cells were transfected with p53 siRNA prior to metformin-treatment ( Fig. 6E and F) .
IFI16-knockdown significantly suppresses metformin-mediated growth arrest and migratory inhibition in HASMCs.
Subsequently, the present study aimed to investigate the role of IFI16 in metformin-mediated suppressive effects. IFI16 siRNA significantly attenuated endogenous IFI16 expression, thus confirming that IFI16 was knocked down in HASMCs transfected with IFI16 siRNA (Fig. 7A and B) . Furthermore, downregulation of IFI16 markedly decreased the expression levels of AMPK and p-AMPK; however, the expression levels of p53 were not significantly altered in response to IFI16 siRNA (Fig. 7C and D) . Similarly, the mRNA expression levels of IFI16 and AMPK were decreased in IFI16 siRNA-transfected cells. IFI16 siRNA had no significant effect on p53 mRNA expression (Fig. 7E) .
Through cell counting, cell cycle assay and CCK-8 assay, the present study demonstrated that IFI16-silenced cells exhibited increased proliferation compared with the control cells. Notably, IFI16-knockdown markedly suppressed metformin-induced cell growth inhibition, g 1 phase cell cycle arrest and cell viability inhibition (Fig. 8A-D) . In addition, IFI16 siRNA transfection induced an increase in cell migration. As expected, metformin hardly had an effect on the migration of IFI16-silenced cells (Fig. 8E and F) .
Metformin upregulates IFI16 and p-AMPK expression through activating p53 in HASMCs.
To investigate the molecular mechanism underlying p53-knockdown-induced suppression of metformin-mediated growth arrest and migratory inhibition, HASMCs were transfected with p53 siRNA followed by metformin stimulation for 24 h. Western blot analysis indicated that metformin upregulated ATM, p-ATM (Ser-1981), p53, p-p53 (Ser-15), IFI16 and p-AMPK expression in p53 siRNA-untreated cells; however, metformin had no significant effect on IFI16 and p-AMPK expression in p53-silenced cells. Conversely, metformin was able to potentiate ATM and p-ATM expression in p53-silenced cells (Fig. 9) .
IFI16 is required for metformin-induced upregulation of p-AMPK.
In order to investigate the molecular mechanism underlying IFI16-knockdown-induced suppression of metformin-mediated suppressive effects, HASMCs were transfected with IFI16 siRNA followed by metformin stimulation for 24 h. Western blot analysis indicated that, although p53 expression was increased in IFI16-silenced cells in response to metformin, IFI16-knockdown markedly suppressed the metformin-induced increase in p-AMPK expression (Fig. 10) .
Discussion
Previous studies have suggested that metformin exerts significant cardioprotective effects alongside its fundamental role as an antidiabetic agent (10, 11) . The mechanism of action of metformin in atherosclerosis is associated with AMPK (29, 30) . It has previously been reported that numerous cytokines, chemokines and growth factors regulate smooth muscle cell proliferation and the progression of atherosclerosis (31, 32) . Increased proliferation of smooth muscle cells has been observed during early atherosclerosis (1) . Smooth muscle cell migration into the intima is considered evidence that smooth muscle cell migration from the media is important in atherogenesis (4) .
Activation of AMPK by metformin antagonizes the proliferation and migration of HASMCs (14) . Consistent with the results of the present study, treatment with metformin can significantly inhibit the growth and migration of HASMCs via activation of AMPK.
Previous studies have reported that AMPK and p53 serve important roles in metformin-mediated cell growth arrest and migratory inhibition (21, 22, 33) . The present study indicated that p53-knockdown resulted in downregulation of IFI16, AMPK and p-AMPK. Furthermore, metformin has been reported to activate p53 via ATM, in order to upregulate IFI16 and p-AMPK; however, in the present study, metformin had no significant effect on activation of IFI16 and p-AMPK in p53-silenced HASMCs. These findings suggested that p53 is required for metformin-mediated activation of IFI16 and AMPK, and is essential for metformin-mediated suppressive effects in HASMCs.
T he present st udy f u r t her exa m i ned whet her metformin-mediated growth arrest and migratory inhibition of HASMCs in an IFI16-dependent manner. IFI16 siRNA had no significant effects on p53 expression, whereas it decreased the levels of AMPK and p-AMPK. Furthermore, metformin had no significant effects on antagonizing cell proliferation and migration, and activating AMPK in IFI16-silenced HASMC. These results indicated that the metformin-induced upregulation of p53 may activate AMPK in an IFI16-dependent manner, and IFI16 may be required for metformin-mediated inhibition of HASMC proliferation and migration. Notably, IFI16 has been reported to serve a central role in suppressing cell proliferation (34) . Therefore, in the present study, it was also hypothesized that the antiproliferative and antimigratory effects of metformin may be attributed to IFI16 activation. The present study demonstrated that metformin inhibits cell proliferation and migration of primary HASMCs via upregulation of p53 and IFI16. To the best of our knowledge, the present study is the first, to the best of our knowledge, to demonstrate that activation of AMPK by metformin antagonizes proliferation and migration, and these activities require the participation of p53 and IFI16 in primary HASMCs. Further in vivo studies are required to clarify the molecular mechanisms underlying the association between the suppressive effects of metformin and the ATM-p53-IFI16-AMPK pathway in HASMCs.
In conclusion, the present study indicated that metformin may inhibit HASMC proliferation and migration through activating the ATM-p53-IFI16-AMPK pathway. In addition, p53 and IFI16 may be required for metformin-mediated suppressive effects and activation of AMPK in HASMCs. These findings suggested that metformin could be considered a potential therapeutic agent used to reduce the risk of atherosclerosis.
